Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142298 | 0.91 | HRH3 (0.39) | ASIC3HRH3KCNH2CYP3A4MCHR1 | |
| SCHEMBL4141821 | 0.88 | ALDH1A1 (0.39) | ASIC3HRH3KCNH2CYP3A4MCHR1 | |
| SCHEMBL4141241 | 0.87 | PGR (0.39) | HRH3KCNH2MCHR1 | |
| SCHEMBL4139649 | 0.86 | HRH3 (0.37) | ASIC3HRH3KCNH2CYP3A4MCHR1 | |
| SCHEMBL4136027 | 0.86 | ASIC3 (0.39) | ASIC3HRH3KCNH2CYP3A4MCHR1 | |
| SCHEMBL4128057 | 0.85 | HRH3 (0.38) | ASIC3HRH3KCNH2MCHR1OPRM1 | |
| SCHEMBL4128192 | 0.85 | HRH3 (0.39) | ASIC3HRH3KCNH2CYP3A4MCHR1 | |
| SCHEMBL4142343 | 0.85 | HRH3 (0.40) | ASIC3HRH3KCNH2CYP3A4CYP1A2 | |
| SCHEMBL4140206 | 0.85 | HRH3 (0.40) | ASIC3HRH3KCNH2CYP3A4MCHR1 | |
| SCHEMBL4128761 | 0.84 | HRH3 (0.38) | ASIC3HRH3KCNH2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | ASIC3 388/4885HRH3 1/4885KCNH2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.